ID: ALA4873390

Max Phase: Preclinical

Molecular Formula: C29H36N6O4S

Molecular Weight: 564.71

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COc1ncc(C2=CCOCC2)cc1S(=O)(=O)Nc1cncc(-c2ccc(CN3CCN(C(C)C)CC3)nc2)c1

Standard InChI:  InChI=1S/C29H36N6O4S/c1-21(2)35-10-8-34(9-11-35)20-26-5-4-23(17-31-26)24-14-27(19-30-16-24)33-40(36,37)28-15-25(18-32-29(28)38-3)22-6-12-39-13-7-22/h4-6,14-19,21,33H,7-13,20H2,1-3H3

Standard InChI Key:  CLFPTIZZKYEKLN-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta/p85-alpha 1508 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-alpha/p85-alpha 2589 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3K p110 beta/p85 alpha 919 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-gamma subunit 5411 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 564.71Molecular Weight (Monoisotopic): 564.2519AlogP: 3.68#Rotatable Bonds: 9
Polar Surface Area: 109.78Molecular Species: NEUTRALHBA: 9HBD: 1
#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 7.06CX Basic pKa: 8.13CX LogP: 0.92CX LogD: 0.83
Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.42Np Likeness Score: -1.36

References

1. Down K, Amour A, Anderson NA, Barton N, Campos S, Cannons EP, Clissold C, Convery MA, Coward JJ, Doyle K, Duempelfeld B, Edwards CD, Goldsmith MD, Krause J, Mallett DN, McGonagle GA, Patel VK, Rowedder J, Rowland P, Sharpe A, Sriskantharajah S, Thomas DA, Thomson DW, Uddin S, Hamblin JN, Hessel EM..  (2021)  Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.,  64  (18.0): [PMID:34510892] [10.1021/acs.jmedchem.1c01102]

Source